Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HRH2 | P25021 | 5/20 | 0.38 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891166 | 0.94 | CTSS (0.46) | CALCRLCTSSCTSKTSHRKMT2A | |
| SCHEMBL5891240 | 0.89 | CTSS (0.51) | CALCRLCTSSCTSKTSHRKMT2A | |
| SCHEMBL5891156 | 0.87 | CALCRL (0.42) | CALCRLCTSSCTSKTSHRKMT2A | |
| SCHEMBL5142485 | 0.83 | CALCRL (0.46) | CALCRLTSHRKMT2AHRH2HRH1 | |
| SCHEMBL4677918 | 0.81 | MAPK1 (0.52) | CALCRLCTSSCTSKTSHRKMT2A | |
| SCHEMBL5141586 | 0.81 | CALCRL (0.49) | CALCRLCTSSCTSKTSHRKMT2A | |
| SCHEMBL5891753 | 0.81 | CALCRL (0.48) | CALCRLTSHRKMT2AHRH2HRH1 | |
| SCHEMBL5891355 | 0.80 | ITGB3 (0.47) | CALCRLTSHRKMT2AHRH2HRH1 | |
| SCHEMBL5143114 | 0.79 | CALCRL (0.42) | CALCRLCTSKTSHRKMT2AHRH2 | |
| SCHEMBL5142544 | 0.79 | TSHR (0.59) | CALCRLCTSSCTSKTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | ELI LILLY AND COMPANY | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254374-A1 | Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases | XPNPEP1, XDH, SERPINC1 | CALCRL 1475/4885CTSS 3515/4885CTSK 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.